Frequently Asked Questions

The Frequently Asked Questions (FAQs) below answer some of the most commonly asked questions patients have. Please check this section if you have questions, and click on the links below to learn more about IBgard.®

1 Hungin, A. P S, L. Chang, G. R. Locke, E. H. Dennis, and V. Barghout. 2005. “Irritable Bowel Syndrome in the United States: Prevalence, Symptom Patterns and Impact.” Alimentary Pharmacology and Therapeutics 21 (11): 1365–75. doi:10.1111/j.1365-2036.2005.02463.x.

2 Cash, Brooks, Sean Sullivan, and Victoria Barghout. 2005. The American Journal of Managed Care 11 (1 Suppl): S7-16. doi:2834 [pii].

3 Drossman et al. J. Clin. Gastroenterol. 2009:43(6) 541-550.

4 Rome IV: Functional Gastrointestinal Disorders, Disorders of Gut-Brain Interaction, Fourth Edition. 2016.

5 González-Castro, Ana M, Cristina Martínez, Eloísa Salvo-Romero, Marina Fortea, Cristina Pardo-Camacho, Teresa Pérez-Berezo, Carmen Alonso-Cotoner, Javier Santos, and María Vicario. 2016. “Mucosal Pathobiology and Molecular Signature of Epithelial Barrier Dysfunction in the Small Intestine in Irritable Bowel Syndrome.” Journal of Gastroenterology and Hepatology, 53–63. doi:10.1111/jgh.13417.

6 Holtmann, Gerald J, Alexander C Ford, and Nicholas J Talley. 2016. “Pathophysiology of Irritable Bowel Syndrome.” The Lancet Gastroenterology & Hepatology 1 (2). Elsevier: 133–46. doi:10.1016/S2468-1253(16)30023-1.

7 Hawrelak, J.A. et al,. Alternative Medicine Review Vol 14, #4 2009, pg. 380-384.

8 Juergens, UR, M Stober, and H Vetter. 1998. European Journal of Medical Research 3 (12): 539–45.

9  Hawthron M et al (1988): Aliment Pharmacol Ther. 2(2):101-18.

10 Liu, Boyia; Fan, Lua; Balakrishna, Shrilathaa; Sui, Aiweia; Morris, John B.b; Jordt, Sven‐Erica,* Pain: October 2013 - Volume 154 - Issue 10 - p 2169–2177. doi: 10.1016/j.pain.2013.06.043.

11 Qinghua Yu, Pengcheng Li & Qian Yang (2010), Pharmaceutical Biology, 48:7, 816-821, DOI: 10.3109/13880200903283681.

12 Camilleri, Michael, and Donald E. Williams. 2000. PharmacoEconomics 17 (4): 331–38. doi:10.2165/00019053-200017040-00003.

13 Cash, Brooks, Michael Epstein, and Syed Shah. 2017. “In Patients with Irritable Bowel Syndrome-Mixed (IBS-M), a Novel Peppermint Oil Formulation Designed for Site Specific Targeting (PO-SST) in the Small Intestine Improves the 8 Symptoms That Comprise the Total IBS Symptoms Score (TISS).” In Digestive Disease Week. Chicago, IL.

14 Goerg, K.J. et al., Aliment Pharmacol Ther 2003; 17:445-451.

15 IBSREST™, a randomized placebo-controlled study of IBgard. Peer-reviewed and published in Dig. Dis. and Sci. 2016.

16 Kearns, G. L., Chumpitazi, B. P., Abdel-Rahman, S. M., Garg, U. & Shulman, R. J. BMJ Open 5, e008375 (2015).

17 Quigley, Eamonn, Michael Fried, Kok-Ann Gwee, Igor Khalif, Pali Hungin, Greger Lindberg, Zaighman Abbas, et al. 2015. World Gastroenterology Organisation Global Guideline. doi:10.1016/j.ajg.2009.12.016.

18 Cash, Brooks D., Michael S. Epstein, and Syed M. Shah. 2016. “A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms.” Digestive Diseases and Sciences 61 (2). Springer US: 560–71. doi:10.1007/s10620-015-3858-7.

19 Swift, Diana, and M Bilal. 2016. AGA Reading Room.

20 Ford, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008). BMJ, 337(a2313), 1–11.

21 De Roest, R. H., Dobbs, B. R., Chapman, B. A., Batman, B., O’Brien, L. A., Leeper, J. A., … Gearry, R. B. (2013). International Journal of Clinical Practice, 67(9), 895–903.

22 Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015). Gut, 64(1), 93–100.

23 Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., & Simrén, M. (2015). Gastroenterology, 149(6), 1399–1407.

24 Nwosu, Benjamin Udoka, Louise Maranda, and Ninfa Candela. 2017. Plos One 12 (2): e0172183. doi:10.1371/journal.pone.0172183.

25 Khayyat, Yasir, and Suzan Attar. 2015. Oman Medical Journal 30 (2): 115–18. doi:10.5001/omj.2015.25.

26 Levings, Jessica

27 Tazzyman, S., Richards, N., Trueman, A. R., Evans, A. L., Grant, V. A., Garaiova, I., Plummer, S. F., Williams, E. A., Corfe, B. M. (2015). BMJ Open Gastroenterology, 2, 1–8.

28 Bischoff et al. BMC Gastroenterology. 2014: 14:189.

29 Rapin JR., Wiernsperger, N. Possible links between intestinal permeability and food processing: a potential therapeutic niche form glutamine. Clinics. 2010:65(6):635-43

30 Rozza AL, Hiruma-Lima CA, Takahira RK, Padovani CR, Pellizon CH. Effect of menthol in experimentally induced ulcers: pathways of gastroprotection. Chem Biol Interact. 2013:206:272-278.

31 Rozza AL, Meira de Faria F, Souza Brito AR, Pellizzon CH. The gastroprotective effect of menthol: involvement of anti-apoptotic, antioxidant and anti-inflammatory activities. Plus One. 2014:9:1-6.


The IBgard® Difference

Access to this section is intended for Healthcare Practitioners only.

Please confirm below that you are a Healthcare Practitioner or click here to return to the consumer section of the site.